Abstract. Prostate cancer is characterized by the recurrent translocation of ETS transcription factors, including ETS variant 1 (ETV1) [also known as ETS-related 81 (ER81)]. Transgenic ETV1 mice develop prostatic intraepithelial neoplasia, yet the mechanisms by which ETV1 exerts its deleterious function remain largely unexplored. In this study, we demonstrated that ETV1 is capable of binding to the matrix metalloproteinase-7 (MMP-7) gene promoter both in vitro and in vivo. ETV1 stimulated the activity of the MMP-7 promoter, which was suppressed upon mutation of two ETV1 binding sites located within 200 base pairs upstream of the MMP-7 transcription start site. ETV1 overexpression in human LNCaP prostate cancer cells induced endogenous MMP-7 gene transcription, whereas ETV1 downregulation had the opposite effect. While MMP-7 overexpression did not influence LNCaP cell proliferation, it increased cell migration, which may be important during later stages of tumorigenesis. Finally, MMP-7 mRNA was significantly overexpressed in human prostate tumors compared to normal tissue. Together, these results showed that MMP-7 is a bona fide ETV1 target gene, implicating that MMP-7 upregulation is partially responsible for the oncogenic effects of ETV1 in the prostate.
Introduction

ETS variant 1 (ETV1) [also known as ETS-related 81 (ER81)
is a transcription factor that belongs to a large family of proteins characterized by a ~85 amino acid-long ETS DNA-binding domain (1) (2) (3) (4) (5) . ETV1 expression is developmentally and tissuespecifically controlled (1, (6) (7) (8) (9) , suggesting that ETV1 plays an important ontogenetic role. ETV1-knockout mice display limb ataxia, abnormal flexor-extensor posturing of their limbs and an anomalous development of sensory neurons and muscle spindles. Due to these defects, ETV1-knockout mice die 3-5 weeks after birth (10, 11) .
The transcriptional activity of ETV1 is regulated by posttranslational modification. Central to this is the activation of the mitogen-activated protein (MAP) kinase pathway (12) . MAP kinases phosphorylate ETV1 on two serine and two threonine residues and an additional two serine residues are phosphorylated by MAPKAP kinases that are activated by MAP kinases. As a consequence of its phosphorylation, ETV1 transcriptional activity becomes greatly enhanced (13) (14) (15) (16) . In addition to phosphorylation, ETV1 may be acetylated on two lysine residues, which is due to p300 (or its paralog CBP) and PCAF, acetyltransferases that bind to ETV1 and are known coactivators (17) (18) (19) (20) . Importantly, MAP kinases appear to stimulate the acetyltransferase activity of p300 and the resultant acetylation of ETV1 also increases its transactivation potential (18) . Moreover, ETV1 interacts with steroid receptor coactivators that are activated by MAP kinase phosphorylation (21) (22) (23) . Thus, ETV1 may be an important downstream effector of a plethora of signals that funnel through the MAP kinase pathway.
The first indication that ETV1 is involved in tumorigenesis emerged from the analysis of Ewing tumors, which arise as a consequence of chromosomal translocations affecting the EWS gene (24, 25) . In particular, the N-terminus of EWS, which represents a potent transactivation domain (26) , was found to be translocated onto the C-terminus of ETV1, including its DNA-binding domain (6) . This results in an oncogenic EWS-ETV1 fusion protein that is constitutively activated and not dependent on MAP kinase stimulation. However, more recently other chromosomal translocations involving ETV1 were observed in prostate tumors, leading to the overexpression of ETV1 (27) (28) (29) (30) (31) . Mimicking this ETV1 overexpression in transgenic mouse models induced the development of prostatic intraepithelial neoplasia, the precursor of prostate carcinomas, indicating that ETV1 overexpression is an underlying cause of prostate cancer initiation (28, 32) . Lastly, copy number amplification of the ETV1 gene was found in ~40% of melanomas (33) , suggesting that ETV1 overexpression also contributes to skin cancer. Consistently, downregulation of ETV1 in melanoma cells suppressed proliferation and anchorageindependent growth, whereas the overexpression of ETV1 led to the transformation of immortalized melanocytes. However, this transforming activity of ETV1 was dependent on the coexpression of molecules that induce MAP kinase activity, N-Ras or B-Raf, suggesting that post-translational modification of ETV1 is required for its transforming activity (33) . ETV1 ultimately affects tumorigenesis by dysregulating gene transcription. Thus, the identification of ETV1 target genes merits further attention, since this will increase our understanding of prostate tumorigenesis and point out potential avenues of therapeutic intervention. Currently, only a few validated ETV1 target genes are known. This includes human telomerase reverse transcriptase (34) , which is upregulated in the vast majority of all tumors, where it is responsible for maintaining telomere length that is crucial for unlimited proliferation (35, 36) . Another ETV1 target gene is HER2/ Neu (37), which is overexpressed in ~10% of all prostate tumors. However, HER2/Neu overexpression increases with the progression of the disease and has been observed in excess of 50% of all androgen depletion independent prostate tumors in a number of studies (38) (39) (40) . Furthermore, the transforming growth factor-β (TGF-β) signaling pathway inhibitor Smad7 is an ETV1 target gene (41) . TGF-β signaling is a prominent tumor-suppressing pathway that is intracellularly relayed via the receptor-regulated R-Smad proteins (42) . Smad7 is different from the R-Smads and antagonizes them by preventing their phosphorylation by TGF-β type I receptors and by downregulating TGF-β receptors through the recruitment of ubiquitin ligases. Accordingly, Smad7 overexpression may be linked to tumor formation and, indeed, has been observed in several types of cancers (43) . In this study, we investigated whether matrix metalloproteinase-7 (MMP-7) is a bona fide ETV1 target gene in prostate cancer cells.
Materials and methods
Electrophoretic mobility shift assays. The following oligonucleotide pairs were hybridized to generate double-stranded MMP-7 promoter oligonucleotides: -55 ETS, 5'-ATGAGTCACCTATT TCCACATTCGAGGCTG-3' and 5'-CTCAGCCTCGAATGTG GAAATAGGTGACTC-3'; -144 ETS, 5'-ATAACGATGTAATA CTTCCTCGTTTT-3' and 5'-ACTAAAACGAGGAAGTATTA CATCGTT-3'; -168 ETS, 5'-CATTGTGTGCTTCCTGCCAAT AACG-3' and 5'-CATCGTTATTGGCAGGAAGCACACA-3' . Double-stranded oligonucleotides were labeled with 32 P-dATP using Klenow DNA polymerase (44) . Binding reactions were performed in 10 µl of 20 mM HEPES pH 7.4, 25 mM NaCl, 12% glycerol, 0.01% Tween 20, 2 mM DTT, 0.1 µg/µl bovine serum albumin and 0.05 µg/µl poly(dIdC) * (dIdC). Where indicated, bacterially expressed and purified ETV1 encompassing amino acids 249-477 (13), 0.5 µl anti-ETV1 antibody (C-20; Santa Cruz Biotechnology, Inc.), unlabeled double-stranded E74 or mE74 oligonucleotide (45) were added together with 32 P-labeled oligonucleotide to the reaction mix. Reactions were allowed to proceed for 20 min at 4˚C. Resulting DNA-protein complexes were then separated on native polyacrylamide gels in a cold room and visualized by autoradiography of the dried gels.
Chromatin immunoprecipitation (ChIP) assays. Human LNCaP prostate cancer cells were grown in 10% charcoalstripped serum with or without 1 nM mibolerone and ChIP assays were performed as described (46) . To amplify a 270-bp fragment of the human MMP-7 promoter, a nested PCR was performed according to the following program: 98˚C for 2 min; 6 cycles of 98˚C for 30 sec, 64˚C for 30 sec (-1˚C/cycle), 72˚C for 25 sec; 20 cycles (first PCR) or 19 cycles (second PCR) of 98˚C for 30 sec, 58˚C for 30 sec, 72˚C for 25 sec (+1 sec/cycle) and 4 min at 72˚C. For the first PCR, MMP-7pro-for1 (5'-GTCCTGAATGATACCTATGAGAGC-3'; -290 to -267 of the MMP-7 promoter) and MMP-7pro-rev1 (5'-CCAGAGACAATTGTTCTTGGACC-3'; +38 to +16 of the MMP-7 promoter) were utilized as primers, and MMP-7pro-for2 (5'-CATGGAGTCAATTTATGCAGCAGAC-3'; -232 to -208 of the MMP-7 promoter) and MMP-7pro-rev1 for the second PCR. For amplification of a 338-bp fragment of the human MDM2 promoter, the same PCR program was employed (32 repeats at a 58˚C annealing temperature) with previously described primers (47) . Amplified promoter DNA fragments were visualized by ethidium bromide staining on agarose gels (48) .
Luciferase assays. The human MMP-7 promoter (-301 to +52) was amplified by PCR from genomic DNA and cloned into the luciferase reporter construct, pGL2-Basic (Promega). Site-directed mutagenesis was performed to change the ETS core sequence at -55 and/or -168 from GGAA to CCAA. All constructs were verified by DNA sequencing. Human embryonic kidney 293T cells were grown in polylysine-coated 12-well plates (49) and transiently transfected by the calcium phosphate coprecipitation method (50) . MMP-7 (500 ng) reporter gene construct, 50 ng CMV-lacZ, 1 µg pBluescript KS + , and indicated amounts of vector or ETV1 expression construct were employed. In case of rabbit kidney RK13 cells, 500 ng MMP-7 reporter gene construct, 1.2 µg pBluescript KS + , 30 ng pEV3S vector or ETV1 expression construct, and 100 ng HER2/Neu-V664E plasmid (51) were used. Thirty-six hours after transfection, cells were lysed (52) and the cleared lysate was employed to measure luciferase activity as described (53) .
Retroviral infection.
To downregulate human ETV1, shRNA targeting the sequence 5'-UUCGATGGAGACAUCAAAC-3' was cloned into pSIREN-RetroQ (Clontech). To overexpress ETV1, murine ETV1 cDNA was cloned into pQCXIP (Clontech). Retrovirus was then produced in 293T cells according to standard procedures (54) and employed to infect LNCaP cells two times within 24 h, which were then grown for an additional 72 h (55). Overexpression or downregulation of ETV1 was ascertained by standard western blotting procedures of cell extracts (56) and utilizing secondary antibodies coupled to horseradish peroxidase and employment of enhanced chemiluminescence (57) . Similarly, retrovirus expressing MMP-7 shRNA (shRNA#1, 5'-GGGAACAGGCUCAGGACUA-3'; shRNA#4, 5'-CCUACAGGAUCGUAUCAUA-3') or human MMP-7 cDNA was generated and utilized.
RT-PCR. Total RNA was extracted from LNCaP cells employing TRIzol (Invitrogen) and ~50 ng RNA was used for amplification with the Access Quick RT-PCR kit (Promega) (58) . The following PCR program was utilized: 48˚C for 45 min; 96˚C for 2 min; 25-35 repeats of 95˚C for 30 sec, 58˚C for 45 sec and 68˚C for 45 sec; final extension for 5 min at 68˚C. The MMP-7 primers used were 5'-TGTGGAGTGCCAGATGTTGCAG-3' and 5'-CTAAATGGAGTGGAGGAACAGTGC-3' , resulting in a 642 bp cDNA fragment. GAPDH mRNA was assayed as described (59) . For determining MMP-7 mRNA levels in cells expressing MMP-7 shRNA, a two-step reaction was performed. First, RT-PCR was carried out with primers MMP-7-b-for (5'-AGATGTGGAG TGCCAGATGT-3') and MMP-7-a-rev (5'-CCAATGAATGAA TGAATGGATG-3') using the PCR program: 48˚C for 45 min; 96˚C for 2 min; 20 repeats of 95˚C for 30 sec, 56˚C for 30 sec, and 68˚C for 30 sec; final extension for 4 min at 68˚C. Second, PCR was carried out with MMP-7-b-for and MMP-7-b-rev (5'-TAGAC TGCTACCATCCGTCC-3') primers employing iProof high-fidelity DNA polymerase (BioRad) with the PCR program: 98˚C for 2 min; 30 repeats of 98˚C for 30 sec, 56˚C for 30 sec, and 72˚C for 30 sec; final extension for 4 min at 72˚C, resulting in a 357-bp cDNA product. Similarly, ETV1 expression was analyzed using hETV1-RT-for (5'-TCCCTCCATCGCAGT CCATACCAG-3') and hETV1-RTrev (5'-GTGGCAGCTAGG CACTTCTGAGTC-3') primers in the RT-PCR reaction (15 repeats) followed by 20 cycles of nested PCR with hETV1-RT-for and hETV1-RT-rev-new (5'-CATATGCAAAATCTCTGG GTTCCTG-3') primers, generating a 291-bp cDNA product. All resultant cDNA fragments were electrophoresed on 1.5% agarose gels and stained with ethidium bromide (60) .
Proliferation assay. LNCaP cells were infected with the indicated retrovirus and selected for at least four days with 1 µg/ml puromycin. Thereafter, cells were seeded into 96-wells (61) and one day later (designated as Day 0) for the first time were analyzed with an MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay (Trevigen) according to the manufacturer's instructions. Further measurements were taken 2, 3 or 5 days thereafter.
Migration assay. Puromycin-selected LNCaP cells (2x10 5 ) (as mentioned above) were seeded into a 24-well format cell culture insert with an 8 µm pore size (353097; Becton-Dickinson) in serum-free media. Migration towards media containing 10% fetal calf serum was measured after 24 h. Migrated cells on the bottom of the membrane were visualized using the Hemacolor staining kit (EMD Millipore) and then counted.
Results
Binding of the ETS transcription factor ETV1 to the MMP-7 gene promoter. Previous reports indicate that the MMP-7 gene
is transcriptionally activated by a number of ETS transcription factors (62, 63) . Thus, we reasoned that MMP-7 may be a new ETV1 target gene in prostate cancer cells. To prove this, we first assessed whether ETV1 directly binds to the MMP-7 gene promoter. We analyzed the human MMP-7 promoter for the presence of potential ETV1-binding sites, which have the consensus sequence 5'-ACCGGAAGT-3'; the GGAA core is the most important determinant of the DNA-binding affinity (64) . Three such ETS sites are present in the MMP-7 promoter (Fig. 1A) , which match to a varying degree to the ETV1-consensus binding sequence (Fig. 1B) .
To study which of these three ETS sites would be bound by ETV1, we performed electrophoretic mobility shift assays. When ETV1 was incubated alone with respective radioactively labeled oligonucleotides, ETV1 binding was not observed (Fig. 1C) . However, previous studies showed that ETV1 DNA binding is inhibited in vitro by its C-terminus, but an additional antibody recognizing its C-terminus alleviates this intramolecular inhibition (37, 41) . This intramolecular inhibition appears to be especially important at the ETV1-binding sites that do not match the consensus binding sequence, as is the case for all three ETS sites within the MMP-7 promoter (Fig. 1B) . Thus, we also included an antibody recognizing the ETV1 C-terminus in the binding reaction and observed strong binding of ETV1 to the -168 ETS site, weak binding to the -55 ETS site, while no binding to the -144 ETS site was observed (Fig. 1C) . To examine binding specificity, we also performed competition experiments with the E74 site that completely matches the ETV1-binding site consensus and readily interacts with ETV1 and other ETS proteins (12, 65) . Unlabeled E74 oligonucleotide efficiently reduced ETV1 binding to the radioactively labeled -168 and -55 ETS sites, whereas a mutated E74 oligonucleotide did not (Fig. 1C) . Together, these data demonstrate that ETV1 is capable of binding to the MMP-7 promoter at two sites in vitro.
To examine whether ETV1 also binds in vivo to the MMP-7 promoter, we performed ChIP assays in LNCaP cells. Since ETV1 binding was previously shown to cooperate with the androgen receptor (AR) in binding to the prostate-specific antigen enhancer (32), we also investigated the influence of androgen stimulation on MMP-7 promoter interaction. We deprived LNCaP cells of androgen and then induced them for 1 or 8 h with the synthetic androgen, mibolerone. Utilizing anti-ETV1 antibodies, the MMP-7 promoter was immunoprecipitated before and after mibolerone stimulation (Fig. 2, left  panels) , showing that ETV1 may bind to the MMP-7 promoter in cells and that this binding is independent of androgen. Accordingly, anti-AR antibodies did not immunoprecipitate the MMP-7 promoter, nor did the control anti-Rcl antibodies. Furthermore, ETV1 did not interact with the MDM2 promoter (Fig. 2, right panels) , attesting to the specificity of our ChIP assay. Thus, ETV1 binds to the MMP-7 promoter in vivo.
Activation of the MMP-7 promoter by ETV1.
To demonstrate that ETV1 not only binds, but also stimulates the MMP-7 gene promoter, we cloned respective human DNA into a luciferase reporter plasmid. This reporter gene was transfected with increasing amounts of an empty vector or ETV1 expression plasmid into 293T cells. Whereas the empty vector barely affected the MMP-7 luciferase reporter gene activity, ETV1 stimulated the MMP-7 promoter in a dose-dependent manner up to ~20-fold (Fig. 3A) . Next, we tested how mutation of the ETV1-binding sites identified above would affect MMP-7 promoter activity. In the absence of ETV1, mutation of the -55 ETS, -168 ETS site or of both sites had no impact on MMP-7 reporter gene activity in 293T cells (Fig. 3B) . However, in the presence of ETV1, mutation of ETS sites at -55 and -168, individually or combined, reduced MMP-7 promoter activity. As expected, mutation of the -55 ETS site had a weaker effect compared to the mutation of the -168 ETS site, while the strongest effect was observed upon mutation of both ETS sites, reducing ETV1-induced MMP-7 promoter activity by half (Fig. 3B) . The fact that the MMP-7 promoter remained inducible by ETV1 upon mutation of both ETV1-binding sites may be due to the indirect effects of ETV1; such as the induction of another gene encoding a transcription factor that is also capable of stimulating the MMP-7 promoter. We also assessed the ability of ETV1 to induce the MMP-7 promoter in another cell line, RK13. Again, we observed that ETV1 induced MMP-7 promoter activity, and mutation of the ETS sites at -55 and -168 severely compromised this activation (Fig. 3C) . In contrast to the 293T cells, mutation of the -55 and -168 ETS sites even suppressed MMP-7 promoter activity in the absence of ETV1, which was probably due to the fact that RK13 cells harbor endogenous ETV1. We also demonstrated how the induction of ETV1 transcriptional activity by HER2/Neu, a receptor tyrosine kinase that stimulates the MAP kinase pathway and thus the ETV1 transactivation potential (12, 13, 66) , would affect MMP-7 promoter activity. In the absence of ectopic ETV1, HER2/Neu stimulated the MMP-7 promoter, possibly due to endogenous ETV1 in the RK13 cells (Fig. 3C) . Moreover, HER2/Neu cooperated with ectopic ETV1 to stimulate MMP-7 luciferase reporter activity, which was drastically reduced upon mutation of the -55 and -168 ETS sites (Fig. 3C) . Altogether, our promoter studies strongly suggest that ETV1 activates the MMP-7 promoter through the -55 and -168 ETS sites.
Endogenous MMP-7 transcription is activated by ETV1.
To corroborate that ETV1 also stimulates the endogenous MMP-7 promoter, we infected human LNCaP prostate cancer cells with a retrovirus overexpressing ETV1. ETV1 overexpression led to strongly enhanced MMP-7 mRNA levels in LNCaP cells as determined by RT-PCR (Fig. 4A) . By utilizing a limited number of PCR amplifications we were unable to detect MMP-7 mRNA in the absence of ectopic ETV1.
Conversely, we expressed shRNA targeting ETV1 in LNCaP cells. By utilizing more cycles of amplification than mentioned above to detect endogenous MMP-7 expression by RT-PCR, we observed that the downregulation of ETV1 resulted in a robust decrease in MMP-7 mRNA levels compared to cells expressing a control shRNA (Fig. 4B, top  panels) . Western blotting confirmed that ETV1 protein was reduced by ETV1 shRNA (Fig. 4B, bottom panels) . Together, these results indicate that MMP-7 transcription is activated by ETV1 in LNCaP prostate cancer cells.
Role of MMP-7 in LNCaP cells.
To define the importance of MMP-7 for the biology of LNCaP cells, we first elected to downregulate MMP-7 with shRNAs. Similar to ETV1 shRNA, both of the MMP-7 shRNAs employed strongly reduced MMP-7 mRNA levels in LNCaP cells (Fig. 5A) . Downregulation of MMP-7 or ETV1 had no impact on LNCaP cell proliferation (Fig. 5B) , and MMP-7 shRNA also did not affect the ability of LNCaP cells to migrate (Fig. 5C) . In contrast, downregulation of ETV1 reduced LNCaP cell migration (Fig. 5C) , which is similar to the reported reduction of LNCaP cell invasion caused by ETV1 siRNA (28, 67) .
We next infected LNCaP cells with an MMP-7-expressing retrovirus. Although we were unable to detect MMP-7 protein in the control cells, robust MMP-7 expression was observed upon infection with the MMP-7 retrovirus (Fig. 5D) . A change in the cell proliferation was not noted upon MMP-7 overexpression (Fig. 5E ), but LNCaP cell migration was significantly enhanced (Fig. 5F ). These data suggest that ETV1-mediated MMP-7 upregulation may particularly contribute to tumor metastasis, which entails cancer cell migration.
Overexpression of MMP-7 in human prostate tumors. Recurrent translocation of the ETV1 gene and the resultant overexpression of the ETV1 protein contributes to prostate cancer (68) . Therefore, one would predict that MMP-7, as a target gene of ETV1, is upregulated in prostate tumors. To prove this, we analyzed published microarray data (69) . The comparison of 23 normal prostate tissues to 65 prostate carcinomas revealed that MMP-7 mRNA is significantly overexpressed in prostate tumors (Fig. 6) . Thus, MMP-7 may indeed be a physiologically relevant target gene of ETV1 during prostate cancer formation.
Discussion
In this study, we demonstrated that MMP-7 is a bona fide target gene of ETV1 in LNCaP prostate cancer cells based on the following results. First, ETV1 binds to two ETS sites in the MMP-7 promoter in vitro and also interacts with the MMP-7 promoter in LNCaP cells in vivo. Second, ETV1 stimulates an MMP-7 luciferase reporter construct and mutation of two ETV1 binding sites diminished this stimulation. Third, the overexpression or downregulation of ETV1 in LNCaP cells activated or repressed, respectively, the endogenous MMP-7 gene transcription.
Furthermore, our results revealed that MMP-7 gene transcription is significantly upregulated in human prostate tumors. These data complement previous studies demonstrating the presence of MMP-7 mRNA in Northern blot analyses of human prostate tumor samples (70, 71) and analyses in rat models of prostate cancer showing that MMP-7 is upregulated during carcinogenesis (72, 73) . Moreover, it was recently found that serum levels of MMP-7 are increased in metastatic prostate cancer patients, but a difference between the control patients and those with localized disease was not observed (74) . Accordingly, high MMP-7 serum levels were correlated with poor prognosis, strongly indicating that MMP-7 upregulation contributes to the development of aggressive prostate cancer. This would be similar to other types of cancer, for which respective recombinant mouse models prove a causal relationship between MMP-7 and tumorigenesis. For instance, knock out of MMP-7 counteracted colon or pancreatic cancer formation, while MMP-7 overexpression was shown to accelerate breast tumorigenesis induced by HER2/Neu (75) (76) (77) . Notably, our results revealed that HER2/Neu targets ETV1 to stimulate MMP-7 transcription. Thus, HER2/Neu, which is overexpressed in the majority of prostate tumors (38) (39) (40) , may synergize with ETV1 overexpression to induce MMP-7 gene transcription in prostate cancer.
ETV1 overexpression has been shown to increase the migration of PNT2C2 and RWPE-1 prostate cells (30, 78) , whereas ETV1 downregulation decreased LNCaP cell invasion (28, 67) . Similarly, we observed that ETV1 shRNA reduced LNCaP cell migration, but this was not caused by decreased MMP-7 transcription, since MMP-7 shRNA itself did not have an impact on LNCaP cell migration. This may be due to the fact that ETV1 not only affects MMP-7 expression, but potentially the transcription of several other proteinases involved in cell migration, including the ETV1 target gene, MMP-1 (13) . Thus, it is conceivable that MMP-7 downregulation alone will not be sufficient to reduce cell migration. Regardless, the fact that MMP-7 overexpression increased LNCaP cell migration (in the current study) and DU-145 prostate cancer cell invasion (79) indicates the physiological relevance of MMP-7 in prostate cancer. Since MMP-7 antibodies were shown to inhibit the migration of gastric cancer cells (80) and the overexpression of MMP-7 promoted migration in colorectal cancer cells (81, 82) , MMP-7 is not only important for cell migration in prostate cancer, but also in various other neoplasias.
MMPs such as MMP-7 may also promote cell growth by fostering the shedding of growth factors or increasing their bioavailability (83) . Furthermore, MMPs affect apoptosis, angiogenesis and immune surveillance (84, 85) . While invasion or angiogenesis is more important during later cancer stages, growth and survival effects of MMP-7 may contribute to the development of hyperplasia and neoplasia at the onset of prostate cell transformation. Thus, MMP-7 may be one target gene that is critical for the reported development of prostatic intraepithelial neoplasia upon ETV1 overexpression (28, 32) .
In conclusion, our data strongly argue that the upregulation of MMP-7 contributes to the oncogenic phenotype of ETV1 in the prostate. Since dysregulated ETV1 is also implicated in skin, breast and gastrointestinal stromal tumors (33, 86, 87) , our results may not be limited to prostate cancer. As such, inhibiting MMP-7 enzymatic activity using small-molecule drugs may be useful in the treatment of various ETV1-overexpressing tumors.
